REal World MAIA UK OutcomEs

Starting soon

Conditions studied: Myeloma

In brief

This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.

Key facts

Study ID

NCT07532473

Run by

The Royal Wolverhampton Hospitals NHS Trust

People needed

300

Starts

2026-07-01

Expected to finish

2028-07-01

Last updated by the study team

2026-04-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years
• Diagnosis of NDMM
• Not eligible for autologous stem cell transplant at diagnosis
• Received frontline DRd treatment following NICE approval (post-September 2023)
• Minimum 3 months of follow-up data available

You may not qualify if…

• Participation in an interventional clinical trial for first-line therapy
• Insufficient treatment or follow-up data for analysis
• DRd used in relapsed/refractory setting rather than newly diagnosed disease

Where it is running

• The Royal Wolverhampton NHS Trust — Wolverhampton, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.